Abstract 63P
Background
One important limitation of the current standard approach of mobilizing hematopoietic stem cells (HSCs) in the peripheral blood (PB) using granulocyte-colony stimulating factor (G-CSF) for the prophylaxis of chemotherapy induced febrile neutropenia or in donors for PB stem cell transplantation (PBSCT) is insufficient mobilization. Based on our preliminary results on the effect of human chorionic gonadotropin (HCG) on stimulating the peripheral mobilization of HSCs in vivo, the aim of the current study was to assess the effect of the addition of HCG to mobilization with G-CSF on the overall survival (OS) as the primary endpoint in a mouse model of PBSCT.
Methods
Male donor mice (n=20) were pretreated with a single dose of either peg-G-CSF alone (group A, n=10) or HCG + peg-G-CSF (group B, n=10), 5 days prior to PBMC harvest. PBMCs were immediately transplanted to the equivalent number of Busulfan mieloablated female mice by intravenous tail injection and OS was assessed in both recipient groups.
Results
The median OS in the group of recipients transplanted with peg-G-CSF mobilized PBMCs (group A`) was 81 days. In the recipients transplanted with HCG+ peg-G-CSF mobilized PBMCs (group B`} the median OS is not reached at 154 days with 90% of the recipients still being alive.
Conclusions
Addition of HCG to the current standard mobilization approach with G-CSF in donors has almost doubled the survival rate in the recipients of a murine model of PBSCT with the median OS not yet reached after 154 days. This prompts for the translation of the preclinical study`s approach in a human proof-of-principle/feasibility clinical trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Executive Agency for Higher Education, Research and Innovation Funding (UEFISCDI), Ministry of National Education (MEN), Romania.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy
Presenter: MIGUEL GALINDO CAMPOS
Session: Poster session 09
15P - CBL E3 ubiquitin ligases are key inhibitory regulators in PD-1/LAG-3 co-signaling in human cancers, targeted through bispecific co-blockade
Presenter: Luisa Chocarro
Session: Poster session 09
16P - Terminally exhausted CD8+ T cells and increased immunosuppressive soluble factors in malignant ascites of patients with gastric cancer with peritoneal metastasis
Presenter: Hye Sook Han
Session: Poster session 09
17P - Continued expansion of long-lived effect CD8+ T cells associates with durable response post-PD-1 blockade
Presenter: Robert Watson
Session: Poster session 09
18P - Exposure of calreticulin is required for vitamin C immunomediated cancer surveillance
Presenter: Alessandro Cavaliere
Session: Poster session 09
19P - Preclinical and clinical significance of VEGF deprivation in ovarian cancer through a specific active immunotherapy
Presenter: Yanelys Morera
Session: Poster session 09
20P - The essential role of DNA repair in the pharmacological activities of AST-3424
Presenter: Fanying Meng
Session: Poster session 09
21P - Implications of KMT2C knockdown for DNA damage repair in breast cancer
Presenter: Philip Bredin
Session: Poster session 09
22P - Clinical significance of DNA damage response mutations in early stage NSCLC
Presenter: Haoran Zhang
Session: Poster session 09
23P - PMC-309: A highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive
Presenter: Cheon Ho Park
Session: Poster session 09